MAZE
Maze Therapeutics, Inc.
$31.99
-0.85 (-2.59%)
At close · Jul 8
Market Cap
$1.79B
Shares
55,345,261
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.99
Open$32.84
Day$31.45–33.50
52W$12.44–53.65
Avg vol 30d636K
Short int4.1M · 7.3% float · 7.7d
Short vol62%
Last earningsMar 25, 2026
DataJan 2025–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
+22%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+36%
trailing
6-month return
−23%
trailing
YTD return
−23%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $34 — 200d above 50d
Institutional flow
Distributing
1 of 168 funds reported for Jun 30 · net -182 sh shares
Insider flow
Distributing
Net -$2.2M over 90 days · 100% sells
Short interest
Rising
7.33% of float · ▲ +4.1% MoM · 7.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
168 holders — near 1-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
EPS growth
−344%
Y/Y
Free cash flow
$-112.7M
Balance sheet
$189.2M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
+22%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $26 › 200d $34 — 200d above 50d
Institutional flow
Distributing
1 of 168 funds reported for Jun 30 · net -182 sh shares
Insider flow
Distributing
Net -$2.2M over 90 days · 100% sells
Short interest
Rising
7.33% of float · ▲ +4.1% MoM · 7.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
168 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $12
Now $32 · 47%
52-wk high $54
vs 200-day avg -7%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MAZE
this stock
Maze Therapeutics, Inc.
|
$1.79B | -22.8% | — | — | 7.3% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MAZE | +7.2% | +35.7% | -22.7% | +7.2% | -22.8% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +7.4% | +34.8% | -30.2% | +7.4% | -32.1% |